Success Story: Foreign Multiple Myeloma Patient Completes CAR-T Treatment at Chinese Hospital

A foreign multiple myeloma patient successfully completed CAR-T treatment at Jiahui International Hospital and was discharged with promising results.

Jiahui International Hospital

CAR-T therapy

short for “chimeric antigen receptor T-cell therapy,” represents a milestone in individualized cell immunotherapy for human cancers. It involves collecting the patient’s T-cells, genetically modifying them ex vivo to enhance their ability to recognize tumor cells specifically. These engineered “armed” T-cells (CAR-T cells) are then infused back into the patient to target and destroy tumor cells, while also forming memory T-cells for sustained anti-tumor effects. China has approved CAR-T therapy for lymphoma, multiple myeloma, and acute leukemia. The treatment process includes patient screening, bridging therapy, adverse reaction management, and long-term follow-up, requiring close collaboration among various teams, including hematology, cardiology, respiratory medicine, neurology, ICU, and experienced nursing teams.

The patient

an Australian residing in Shanghai, was diagnosed with multiple myeloma in 2008. Despite undergoing various treatments, including chemotherapy, immunotherapy, targeted therapy, and autologous stem cell transplantation, he unfortunately relapsed in 2022 with severe pain and bone damage. But due to the exorbitant cost of treatment in the United States, he has not been able to receive effective treatment.

IASO

BCMA-CAR-T

In July 2023, the BCMA-targeted Equecabtagene Autoleucel Injection developed by IASO Biotech was approved for marketing, specifically for the treatment of relapsed or refractory multiple myeloma adult patients who have undergone at least 3 prior lines of therapy. However, the price is only one-third of the treatment cost in the United States.

After consultation with Director Li Hua and Dr. Zhou Lili from the Hematology Team at Jiahui International Hospital, he decided to undergo this cutting-edge treatment at Jiahui. Throughout the treatment process, he continued working without interruption, only taking leave in the last three weeks for cell infusion, and the entire process went smoothly.

Choosing Jiahui International Hospital for CAR-T treatment not only avoided the hassle of extensive travel but also provided access to international standard medical services, efficient and convenient services, advanced therapies, and state-of-the-art facilities.

Since the approval of Chinese CAR-T therapy

China has established many high-level international CAR-T treatment teams, and more and more foreign and domestic hematologic tumor patients have chosen China for CAR-T treatment, including foreign lymphoma and multiple myeloma patients who have completed treatment and been discharged, as well as many patients from abroad who urgently need CAR-T treatment.

In the future, China will continue to explore innovative concepts and technologies for the clinical application, bringing new hope for cure to more hematologic tumor patients.

���To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

��� #CAR-T Success Story# ��� #Jiahui International #Cancer Center# ��� #International Collaboration# ���️ #Hope For Cure #Hope for patient #jiahui #cancer treatment

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements

🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬

 

Patient 1: 53-year-old Male

Gastric Cancer,
Pancreatic Cancer

Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.

 

Patient 2: 57-year-old Female

Gastric Cancer,
Pancreatic Cancer

Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.

 

🏆 CT041 Achievements 🏆

– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.

– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.

– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.

– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.

– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!

We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com,

or WhatsApp+8613717959070

The Medical Department will contact you as soon as they receive the reports.

 

#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare